Biohaven Ltd (BHVN)
40.69
+0.79
(+1.98%)
USD |
NYSE |
May 03, 16:00
40.68
-0.01
(-0.02%)
After-Hours: 20:00
Biohaven Cash from Financing (TTM): 211.91M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 211.91M |
September 30, 2023 | 496.85M |
June 30, 2023 | 664.05M |
Date | Value |
---|---|
March 31, 2023 | 771.23M |
December 31, 2022 | 767.60M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
211.91M
Minimum
Dec 2023
771.23M
Maximum
Mar 2023
582.33M
Average
664.05M
Median
Jun 2023
Cash from Financing (TTM) Benchmarks
Amgen Inc | -2.169B |
Eli Lilly and Co | 2.772B |
Regeneron Pharmaceuticals Inc | -1.420B |
Viking Therapeutics Inc | 873.23M |
Alnylam Pharmaceuticals Inc | 154.67M |